Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-30), Egetis Therapeutics AB's 3-1 Month Momentum % is 12.90%.
The industry rank for Egetis Therapeutics AB's 3-1 Month Momentum % or its related term are showing as below:
LTS:0ABW's 3-1 Month Momentum % is ranked better than 79.86% of 1385
companies
in the Biotechnology industry
Industry Median: -9.14
vs LTS:0ABW: 12.90
Egetis Therapeutics AB (LTS:0ABW) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Egetis Therapeutics AB 3-1 Month Momentum % Related Terms
LTS:0ABW vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Egetis Therapeutics AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egetis Therapeutics AB 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Egetis Therapeutics AB's 3-1 Month Momentum % falls into.
Egetis Therapeutics AB (LTS:0ABW) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egetis Therapeutics AB (LTS:0ABW) has a 3-1 Month Momentum % of 12.90% as of Aug. 30, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Egetis Therapeutics AB and its competitors. According to the industry distribution chart, Egetis Therapeutics AB ranks #279 out of 1385 companies in the Biotechnology industry, placing it in the top 20.1%.
Is Egetis Therapeutics AB's 3-1 Month Momentum % too high?
Egetis Therapeutics AB's current 3-1 Month Momentum % is 12.90%. Based on the distribution chart, Egetis Therapeutics AB ranks #279 out of 1385 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Egetis Therapeutics AB has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Egetis Therapeutics AB ranks #279 out of 1385 companies for 3-1 Month Momentum %. This places Egetis Therapeutics AB in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Egetis Therapeutics AB and its competitors. Egetis Therapeutics AB's current 3-1 Month Momentum % is 12.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (LTS:0ABW) is currently considered Significantly Overvalued. The stock's GF Value™ is kr5.30, compared to a current price of kr8.02 — trading 51.3% above its estimated fair value. The current 3-1 Month Momentum % is 12.90%. Egetis Therapeutics AB's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Egetis Therapeutics AB (LTS:0ABW), the current 3-1 Month Momentum % is 12.90% as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egetis Therapeutics AB (LTS:0ABW) Overvalued in 2026?
Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued.
The current stock price of kr8.02 is trading 51.3% above its estimated GF Value™ of kr5.30.
GuruFocus considers Egetis Therapeutics AB to be Significantly Overvalued.
Key valuation signals for LTS:0ABW:
3-1 Month Momentum %: 12.90%
GF Value™: kr5.30 vs. price of kr8.02 (51.3% above fair value)
No single metric tells the full story. See the LTS:0ABW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
51GF Score
Get the complete analysis for LTS:0ABW
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0ABW has been successfully added to your 
